Yes. Already, stem cells have been able to help people with conditions like testicular cancer, leukemia, aplastic or refractory anemia, osteoporosis, multiple myeloma, and a group of blood ...

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence ... was recently published in the Journal of Clinical and Translational Pathology.

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence ... Journal of Clinical and Translational Pathology. Journal of Clinical and ...

OGM provides a comprehensive genomic profile that can be used to support more precise prognostic risk stratification “Multiple myeloma is one of the most requested cancer types by customers ...

Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myeloma and the only anti-CD38 antibody for all patient types in this setting Phase 3 CEPHEUS study shows significant ...

Bispecific antibodies enhance immune response by targeting myeloma and immune cells, showing high efficacy in multiple myeloma treatment. Tecvvayli, Talvey, and Elrexfio demonstrate significant ...

CAR-T cell therapy is often impractical for patients needing second-line therapy, according to a presentation from the 2025 CURE Educated Patient® Multiple Myeloma Summit. “CAR-T cell therapy refers ...

Background: Despite advances in the treatment of multiple myeloma, a proportion of patients still hardly achieve desired prognosis. Although microtransplant (MST) has proved promising results in ...

The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: Diagnosis also required -- and still does -- the ...